Denali Therapeutics Inc. (DNLI)

NMS – Real vaqt narxi. Valyuta: USD

25.29

+0.60 (2.43%)

Yopilishda: Aug 12, 2026, 3:59 PM EDT

24.70

-0.57 (-2.26%)

Bozordan keyin: Aug 12, 2026, 4:54 PM EDT

07.08.2026

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum

Denali Therapeutics narrows Q2 loss as Avlayah sales top estimates, with strong launch traction and pipeline updates shaping its outlook.

07.08.2026

Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript

07.08.2026

Denali Therapeutics Q2 Earnings Call Highlights

Denali Therapeutics NASDAQ: DNLI reported $3.6 million in net product revenue from AVLAYAH during the second quarter of 2026, its first full quarter of commercial availability, as the company expanded payer access and advanced two Alzheimer's disease programs into clinical development.

06.08.2026

Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.72 per share a year ago.

06.08.2026

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Strong first full quarter of AVLAYAH™ (tividenofusp alfa-eknm) launch generated $3.6 million in net product revenue Advanced TransportVehicle™ portfolio with two Alzheimer's disease programs now in clinical development $195 million in gross proceeds received in July 2026 from sale of a Priority Review Voucher, bringing pro forma cash, cash equivalents and marketable securities to more than $1.1 billion Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.

Videolar

No Data

There is no data to display

Press-relizlar

06.08.2026

Denali Therapeutics Inc. (DNLI)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Denali Therapeutics Inc. (DNLI)

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum

Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript

Denali Therapeutics Q2 Earnings Call Highlights

Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Videolar

No Data

Press-relizlar

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum

Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript

Denali Therapeutics Q2 Earnings Call Highlights

Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Videolar

No Data

Press-relizlar

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Search stocks

Denali Therapeutics Inc. (DNLI)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Denali Therapeutics Inc. (DNLI)

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum

Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript

Denali Therapeutics Q2 Earnings Call Highlights

Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Videolar

No Data

Press-relizlar

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum

Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript

Denali Therapeutics Q2 Earnings Call Highlights

Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Videolar

No Data

Press-relizlar

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights